Follow @BiologyFool
Recent articles
Here's Why Adverum's Shares Saw a Lower Price Today
The biotech’s gene therapy isn’t helping patients see better.
Here’s Why GW Pharmaceuticals Dropped 12% in August
The cannabis-focused biotech couldn’t hold its post-earnings gains.
Turns Out, It Wasn't Bad News for Intra-Cellular Therapies
Down over 18%, the biotech bounces back.
Here’s Why Align Technology Dropped 12.4% in August
Investors continue to worry about decelerating growth at the orthodontic-device specialist.
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
Here's Why Alexion Pharmaceuticals Dropped 11% in August
It was a roller coaster of a month for the biotech.
Here's Why Nektar Therapeutics Plummeted 38% in August
Manufacturing issues plague the start-up.
Here's Why TherapeuticsMD Jumped 34% in August
The women’s health expert logged a solid second quarter.
Here's How Emergent BioSolutions Procured a Higher Price Today
The U.S. government wants more of its smallpox vaccine.
Trump Wants the VA to Get as Much of This Drug as It Can
How much Johnson & Johnson will actually benefit is unclear.
Here’s Why The Medicines Company Shares Jumped 13.8% Today
The biotech got good news on a clinical trial.
Why Mallinckrodt and Endo International Shares Jumped Today
Investors appear to have some confidence that the companies will settle their opioid lawsuits.
Here's Why Mallinckrodt Dropped 12% Today
Positive clinical-trial results couldn't save the embroiled biotech.
Novo Nordisk Waits for Its Next Launch
The second quarter wasn't too shabby either.
Diplomat Pharmacy Considers Its Options
The company is undergoing a review of strategic alternatives.
Ionis Pharmaceuticals Looks to Partners to Pay the Bills
Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
Becton, Dickinson Accelerates Its Growth
The medical device maker looks to round out its fiscal year with a bang.
Alnylam Adds on Sales, Looks to Pipeline for Further Growth
The biotech could go from one to four marketed drugs in a little over a year.
Momenta Continues Its Transition
Developing novel drugs takes time.
bluebird bio Prepares for Launch
Zynteglo was recently approved in Europe.